Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. The company has a market cap of $148.95 million. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. It currently has negative Earnings. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
The post Eps Expected to Decrease for Kamada Ltd (KMDA) appeared first on Octafinance.